Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilent Technologies Inc (A) vs Kimberly Clark Corp (KMB) Price & Performance

Agilent Technologies IncTrade
Kimberly Clark CorpTrade

Price performance (Past 24H)

Key statistics

Agilent Technologies Inc vs Kimberly Clark Corp — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Kimberly Clark Corp trades at $108.57 (market cap $36.48B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.67%). Which is the better fit depends on your goals.

AKMB
Market Cap
$42.00B$36.48B
Sector
HealthConsumer Staples
52-Week High
$157.20$134.81
52-Week Low
$110.24$93.05
Enterprise Value
$43.55B$42.04B
Dividend Yield
0.69%4.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilent Technologies Inc

Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.

The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.

Kimberly Clark Corp

Kimberly-Clark (KMB) trades at $109.68, up 0.94% with a bullish technical signal. The stock shows strong profitability with 11.79% net margin and 129.43% ROE, though Q2 2026 earnings missed estimates. Recent news highlights China market challenges and dividend stability. Current valuation metrics include P/E of 21.68 and P/S of 2.2, with analyst consensus price target of $113.20 suggesting modest upside potential from current levels.

KMB presents a balanced investment case with solid fundamentals offset by near-term headwinds. The company maintains strong brand positioning and dividend consistency, but faces execution risks from China market disruptions and consumer softness. Wall Street maintains cautious optimism with 61% hold ratings, indicating potential for gradual appreciation if operational challenges are managed effectively.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Agilent Technologies Inc

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.

Read more on A

About Kimberly Clark Corp

With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.

Read more on KMB